New products boost Lundbeck’s 2013 performance

6 February 2014
lundbeck-logo-big

Danish CNS drug specialist Lundbeck (LUND: CO) has reported financials for 2013, showing that revenues increased 3% year-on-year-year to 15.26 billion Danish kroner ($2.76 billion).

Revenue was impacted by the reduced Ebixa (memantine) revenue in Europe, following the anticipated generic erosion. Reported earnings before interest and tax (EBIT) for 2013 was 1,599 million kroner, down 7.4%, corresponding to an EBIT margin of 10.5% for the year. Profit for the period was 855 million kroner, down from 1,165 million kroner in 2012.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



More ones to watch >






Company Spotlight



More Features in Pharmaceutical